Nicotine replacement therapy (NRT) is the common pharmacological treatment for smoking cessation. There appear to be individual differences in the degree to which some formulations of NRT are clinically efficacious. Because of the vastly different speed of nicotine delivery between transdermal (TN) and nasal spray nicotine (NS), some of this individual differences in efficacy may relate to different effects of these products on neurochemical responses. Differences in dopamine transporter genotype, SLAGA3-9 (""""""""protected"""""""") versus SLC6A3- *(""""""""predisposed""""""""), are related to smoking status, perhaps because of differential effects of nicotine on the dopaminergic reward system. A smoking cessation study (project #2) is planned as part of the main center application to examine whether dopamine transporter genotype may predict differential outcome with TN versus NS treatment. This project includes assessment of the reinforcing value of smoking prior to starting NRT. The present pilot study extends and complements the clinical study by examining under controlled conditions whether the reinforcing value of smoking in response to acute exposure to TN versus may be differentially reduced between smokers of one genotype or the other. In this pilot project, we propose to: 1) Compare the reinforcing value of smoking following acute pre- treatment with TN, NS, and placebo between smokers with the SLC6A3- 9 versus SLC6A3-* dopamine genotypes. We predict that the reinforcing value of smoking will be decreased more by NS versus TN (main effect of NRT type) and that this decrease will differ as a function of genotype (genotype x NRT type interaction). The reinforcing value of smoking will be decreased by NS, but not TN, in SLC6A3-* smokers, while the reinforcing value of smoking will be decreased by either NS or TN in SLC6A3-9 smokers. 2) Compare acute objective mood response to TN, NS, and placebo between dopamine genotypes. Although of secondary, we predict that positive subjective responses (e.g. """"""""alert"""""""", """"""""relaxed"""""""") will be increased by NS more in smokers with SLC6A3-* versus SLC6A3-9 genotypes, while differences are expected between groups in mood responses to TN (genotype x NRT interaction). Result of this pilot may help explain possible different clinical efficacy of TN and NS between genotypes and aid in the identification of smokers more likely to benefit from one of the other formulation of NRT (i.e. tailor pharmacotherapy).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA084718-01S2
Application #
6366923
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1999-09-30
Project End
2000-09-29
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
$245,224
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Hsu, Ping-Ching; Lan, Renny S; Brasky, Theodore M et al. (2017) Metabolomic profiles of current cigarette smokers. Mol Carcinog 56:594-606
Hsu, Ping-Ching; Lan, Renny S; Brasky, Theodore M et al. (2017) Menthol Smokers: Metabolomic Profiling and Smoking Behavior. Cancer Epidemiol Biomarkers Prev 26:51-60
Weng, Daniel Y; Chen, Jinguo; Taslim, Cenny et al. (2016) Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog 55:1424-37
Song, Min-Ae; Marian, Catalin; Brasky, Theodore M et al. (2016) Chemical and toxicological characteristics of conventional and low-TSNA moist snuff tobacco products. Toxicol Lett 245:68-77
Schnoll, Robert A; Goelz, Patricia M; Veluz-Wilkins, Anna et al. (2015) Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 175:504-11
David, Sean P; Strong, David R; Leventhal, Adam M et al. (2013) Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 108:2202-11
Bough, K J; Lerman, C; Rose, J E et al. (2013) Biomarkers for smoking cessation. Clin Pharmacol Ther 93:526-38
Perkins, Kenneth A; Parzynski, Craig; Mercincavage, Melissa et al. (2012) Is self-efficacy for smoking abstinence a cause of, or a reflection on, smoking behavior change? Exp Clin Psychopharmacol 20:56-62
Conklin, Cynthia A; Parzynski, Craig S; Salkeld, Ronald P et al. (2012) Cue reactivity as a predictor of successful abstinence initiation among adult smokers. Exp Clin Psychopharmacol 20:473-8
Featherstone, Robert E; Phillips, Jennifer M; Thieu, Tony et al. (2012) Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials. PLoS One 7:e39775

Showing the most recent 10 out of 148 publications